Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers.

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery ) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference 2026

Jun 16, 2026

Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery ) Development Candidates for the Treatment of Alzheimer's Disease

May 12, 2026

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

See More Press Releases

The Conversation (0)

Alert Options

No alert set

INN Article Notification

Instant Daily Weekly

Alert Option

You will be notified when this event occurs. No additional settings needed.